Altimmune (ALT) said Thursday new 48-week data from the Impact phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor agonist, significantly lowered elevated lipids while improving multiple cardio-metabolic risk factors in patients with metabolic dysfunction-associated steatohepatitis, or MASH.

The findings demonstrated reductions in triglycerides and total cholesterol, along with improvements in weight, waist circumference and blood pressure, highlighting pemvidutide's efficacy on key drivers of MASH, the company said.

The data was presented for the first time at the European Association for the Study of the Liver Congress 2026 in Barcelona, Spain.

Results also showed that the safety profile of pemvidutide was maintained at 48 weeks and the tolerability profile was generally favorable without dose titration, the company added.

Shares of Altimmune rose more than 3% in Thursday trading.

Price: 3.07, Change: +0.09, Percent Change: +3.15